The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice
Open Access
|Jan 2012References
- Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele J, et al, editors.4th edition. Lyon, France: International Agency for Research on Cancer; 2008.
- Žakelj Primic M, Bračko M, Pompe-Kirn V, Zakotnik B, editors.Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2010.
- Shipp M, Harrington D, Anderson J, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkincs lymphomas.1993;: 987-94.
- Strojan-Flezar M, Lavrencak J, Zganec M, Strojan P. Image cytometric nuclear texture features in inoperable head and neck cancer: a pilot study.2011;: 40-50.
- Velnar T, Smrdel U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours.2010;: 13-8.
- Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia.2006;: 791-820.
- Molina A. A decade of rituximab: improving survival outcomes in nonHodgkin's lymphoma.2008;: 237-50.
- Jezeršek Novaković B, Benigar A. Treatment of non-Hodgkin's lymphomas with rituximab in Slovene patients.2010;: 167-76.
- Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.2010;: 2373-80.
- Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.2007;: 1857-61.
- Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.2010;: 172-4.
- Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas.1999:: 1244-53.
- Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.2008;: 213-23.
- Pettengell R, Linch D. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma.2003;: 44-8.
- Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.2002;: 235-42.
- Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.2005;: 5027-33.
- Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.2005;: 4117-26.
- Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.2006;: 3121-7.
- Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.2006;: 379-91.
- Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.2010;: 2040-5.
- Horvat M, Jezeršek Novaković B. Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma.2010,: 232-8.
- Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer.2004;: 334-40.
- Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.2010;: 4916-25.
- Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.2000;: 503-11.
- Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas.2008;: 2313-23.
- Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).2008;: 105-16.
Language: English
Page range: 153 - 159
Published on: Jan 2, 2012
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2012 Brigita Gregoric, Vesna Zadnik, Barbara Novakovic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.